Tracking early response to immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. HyperpolarizedInternational journal of molecular sciences · 2023
   Article
2. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.Journal for immunotherapy of cancer · 2022
   Article
3. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers.British journal of cancer · 2021
   Review
4. Assessment of early metabolic progression in melanoma patients under immunotherapy: anEJNMMI research · 2021
   Article
5. Interim [European journal of nuclear medicine and molecular imaging · 2021
   Article
6. Modelling treatment-response rates.Nature biomedical engineering · 2021
   Article
7. Lights and Shadows in Immuno-Oncology Drug Development.Cancers · 2021
   Article

Corrections and comments

• Comment on
  Peripheral CD82020
• Comment on
  Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as